’We expect MNCs to bring in next generation products and improve accessibility’
Mahesh Singhi, Managing Director, Singhi Advisors shares his views and offers insights on the changing regulatory environment in…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Commercial Excellence 2.0
Bart Janssens, Partner and Director, BCG and Rahul Guha, Principal, BCG, in this three part article series, challenge some of the…
Medigene signs licence agreement with Falk Pharma
Falk Pharma will initially concentrate on development in primary biliary cirrhosis (PBC)
Pall unveils expanded product line at INTERPHEX 2014
Recent acquisitions extend upstream and single-use capabilities
Train to Gain
Non compliance with GMP norms has proved costly for some of the biggest Indian pharmaceutical companies. Eager to avoid such…
Initiatives by IDMA
SV Veerramani, President,IDMA, Chairman and Managing Director, Fourrts (India) Laboratories elaborates on endeavours taken by IDMA…
An arduous endeavour?
Indian pharma companies are pushing for 'third country' status from the EU regulatory authorities for India's Schedule M and GMP…
cGMP implementation: From philosophy to practice
Advocating a quality systems approach for cGMP implementation, SM Mudda, Executive Director-Technical & Operations, Micro…
US FDA cGMP regulatory compliance by Indian pharma: An impossible dream?
Ram Balani, CEO-Founder, FDASmart Inc, sheds some light on the compendium of errors committed by Indian pharma manufacturers and…
Surviving a regulatory audit
In the regulatory compliance domain, one of the common failures cited by the regulatory authorities in their warning letters is…